Wollschlaeger BA, Willson TM, Montejano LB, Ronquest NA, Nadipelli VR. Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse. J Opioid Manag. 2017 Jul;13(4):207-20. doi: 10.5055/jom.2017.0389
Ronquest N, Wollschlaeger B, Montejano L, Wilson T, Nadipelli V. Characteristics and treatment patterns of US medicaid patients with opioid use disorder. Poster presented at the 2016 International Conference on Opioids Conference; June 2016. Boston, MA. [abstract] J Opioid Manag. 2016 May; 12(3):227.
Tami-Maury I, Vidrine DJ, Fletcher FE, Danysh H, Arduino R, Gritz ER. Poly-tobacco use among HIV-positive smokers: implications for smoking cessation efforts. Nicotine Tob Res. 2013 Dec;15(12):2100-6. doi: 10.1093/ntr/ntt107.
Hauber AB, Fleischmann J, Lothgren M, Wilson M, Lam A, Dubois D, Sabatowski R. Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective. J Opioid Manag. 2011 Jul 1;7(4):287-96.
Sunyer J, Forastiere F, Pekkanen J, Plana E, Kolz M, Pistelli R. Interaction between smoking and the interleukin-6 gene affects systemic levels of inflammatory biomarkers. Nicotine Tob Res. 2009 Nov;11(11):1347-53.
Monchuk DC, Rousu MC, Shogren JF, Nonnemaker J, Kosa KM. Decomposing the value of cigarettes using experimental auctions. Nicotine Tob Res. 2007 Jan;9(1):93-9.
David SP, Niaura R, Papandonatos GD, Shadel WG, Burkholder GJ, Britt DM, Day A, Stumpff J, Hutchison K, Murphy M, Johnstone E, Griffiths SE, Walton RT. Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res. 2003 Dec 1;5(6):935-42.
Niaura R, Britt DM, Borrelli B, Shadel WG, Abrams DB, Goldstein MG. History and symptoms of depression among smokers during a self-initiated quit attempt. Nicotine Tob Res. 1999 Sep 1;1(3):251-7.